Clinical Trials in Ohio

Showing 1881-1900 of 17,983 trials

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

NCT06444516

The purpose of this study is to evaluate and demonstrate the efficacy and safety of an investigational ocular lubricant formulation in patients with mild to moderate dry eye disease (DED).

Dry Eye Disease

Alcon Research188 participantsStarted Sep 2024

Maitland, Florida, United States • Orlando, Florida, United States • Franklin Park, Illinois, United States +6 more locations

Not Yet RecruitingPhase 132 miles

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

NCT05521698

This phase I trial evaluates the effects of apalutamide, compared to placebo, on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.

Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

University of Wisconsin, Madison80 participantsStarted Apr 2026

Tucson, Arizona, United States • Los Angeles, California, United States • Bethesda, Maryland, United States +3 more locations

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Find Trials by Condition in Ohio

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Conditioning SCID Infants Diagnosed Early

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Responsive Neurostimulation For Loss Of Control Eating

AQT90 FLEX NTproBNP2 Test Kit Matrix Comparison and Sample Stability Verification Study

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors